Immunotherapy of metastases enhances subsequent chemotherapy.
In many multimodal therapies of cancer, postsurgical chemotherapy is administered before immunotherapy for treatment of micrometastatic disease. This sequence may not be the most efficacious. Experiments in which strain 2 guinea pigs bearing syngeneic L10 hepatocarcinomas were given immunotherapy showed that infiltrating immune effector cells not only were tumoricidal but disrupted the characteristically compact structure of metastatic foci. When cytotoxic drugs were administered at the peak of this inflammatory response, the survival rate of the guinea pigs increased significantly. We conclude that postsurgical immunotherapy can enhance the effect of cytotoxic drugs administered subsequently.
D000818:Animals; D000951:Antigens, Neoplasm / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001500:BCG Vaccine / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000628:therapy; D002330:Carmustine / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D006168:Guinea Pigs; D007167:Immunotherapy; D008113:Liver Neoplasms; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000628:therapy
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D001500:BCG Vaccine; D003520:Cyclophosphamide; D002330:Carmustine